Status™ COVID-19/Flu A&B Rapid Test Kit CLIA Waived 25/Box, 20/Case
A Rapid Immunoassay for the Simultaneous Direct Detection and Differential Diagnosis of SARS-CoV-2, Influenza Type A and Type B Antigen from anterior nasal and nasopharyngeal swab specimens
Description
COVID-19
– Anterior nasal swab specimen − Sensitivity 93.8 %, Specificity 100%
– Nasopharyngeal − Sensitivity 93.1 %, Specificity 100%
Flu A – Sensitivity 91.4%, Specificity 95.7%
Flu B – Sensitivity 87.6%, Specificity 95.9%
FDA Emergency Use Authorization (EUA)
Visually read in 15 minutes
Flocked nasopharyngeal swab for superior specimen collection and patient comfort
Additional information
| Weight | 1.12 lbs |
|---|---|
| Dimensions | 6.5 × 11.3 × 3.7 in |
| Brand |
Status |
| Item |
Antigen |
| CLIA |
CLIA Waived |
| Registration |
EUA FDA |
| Category |
Infectious Disease |